IP Library › Granted Patent US 12,440,501
Granted Patent B2
US 12,440,501 · App. 17/428,572 · Granted Oct 14, 2025

Cannabinoid compositions and methods of use thereof for immune modulation

Inventors: Akhil Alugupalli (Horsham, PA); Kishore Alugupalli (Horsham, PA)
Assignee: SRIN Therapeutics, Inc.
A61K31/05A61K9/0019A61K9/1075A61K31/282A61K31/4184A61K31/437A61K31/4523A61K31/506A61K31/519A61K31/655A61K31/704A61K35/17A61K39/0011A61K39/3955A61K47/06A61K47/10A61K47/26A61K47/44A61P35/00A61K2039/505A61K2039/545
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,501
App. No.
17/428,572
Granted
Oct 14, 2025
Kind
B2
Abstract

Compositions comprising one or more phytocannabinoids and methods of use thereof for treatment of cancer, immune modulation, and protecting the immune system are provided.

Claims (36)

1. A method for inhibiting progression of lung cancer, colorectal cancer, or melanoma in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition that is a nanoemulsion comprising:

i) a single cannabinoid isolate that is a cannabidiol isolate, wherein the cannabidiol isolate is present at a concentration of at least 2% to about 12% w/v;

ii) at least 2% w/v olive oil;

iii) water;

iv) at least 0.05% w/v of polysorbate 80; and

v) terpenes consisting of about 0.25% w/v of each of limonene, myrcene, pinene, and linalool,

wherein the subject is being treated with chemotherapy or is recovering from chemotherapy, and the chemotherapy is a platinum-based agent or dacarbazine.

2. The method according to claim 1 , wherein the nanoemulsion is characterized by a mean particle diameter size up to 200 nm.

3. The method according to claim 1 , wherein the pharmaceutical composition is suitable for or formulated for oral administration.

4. The method according to claim 1 , wherein the pharmaceutical composition is suitable for or formulated for topical, oral, or sublingual administration in a solution, spray, drop, strip, cream, or capsule.

5. The method according to claim 1 , wherein the melanoma is BRAF-mutant melanoma.

6. The method according to claim 1 , wherein the subject received a bone marrow transplant or hematopoietic stem cell transplant.

7. The method of claim 1 , wherein the platinum-based agent is carboplatin.

8. The method of claim 1 , wherein the subject has a blood cell composition that is not adversely affected by administration of the pharmaceutical composition and/or administration of the pharmaceutical composition does not alter antibody responses to immunization.

9. A method for inhibiting progression of lung cancer, colorectal cancer, or melanoma in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition that is a nanoemulsion comprising:

i) a single cannabinoid isolate that is a cannabidiol isolate, wherein the cannabidiol isolate is present at a concentration of about 6% to about 12% w/v;

ii) about 20% w/v olive oil;

iii) water;

iv) about 0.1% w/v of polysorbate-80; and

v) terpenes consisting of about 0.25% w/v of each of limonene, myrcene, pinene, and linalool.

10. The method according to claim 9 , wherein the subject has a blood cell composition that is not adversely affected by administration of the pharmaceutical composition and/or administration of the pharmaceutical composition does not alter antibody responses to immunization.

11. The method according to claim 9 , wherein the subject is being treated with chemotherapy or is recovering from chemotherapy, and wherein the chemotherapy is a platinum-based agent or dacarbazine.

12. The method of claim 11 , wherein the platinum-based agent is carboplatin.

13. The method according to claim 9 , wherein the pharmaceutical composition is suitable for or formulated for oral administration.

14. The method according to claim 9 , wherein the pharmaceutical composition is suitable for or formulated for topical, oral, or sublingual administration in a solution, spray, drop, strip, cream, or capsule.

15. The method according to claim 9 , wherein the melanoma is BRAF-mutant melanoma.

16. A method for inhibiting progression of lung cancer, colorectal cancer, or melanoma in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition that is a nanoemulsion comprising:

i) a single cannabinoid isolate that is a cannabidiol isolate, wherein the cannabidiol isolate is present at a concentration of about 6% w/v;

ii) about 20% w/v olive oil;

iii) water;

iv) about 0.1% w/v of polysorbate-80; and

v) terpenes consisting of about 0.25% w/v of each of limonene, myrcene, pinene, and linalool.

17. The method according to claim 16 , wherein the subject has a blood cell composition that is not adversely affected by administration of the pharmaceutical composition and/or administration of the pharmaceutical composition does not alter antibody responses to immunization.

18. The method according to claim 16 , where herein the subject is being treated with chemotherapy or is recovering from chemotherapy.

19. The method according to claim 16 , wherein the pharmaceutical composition is suitable for or formulated for oral administration.

20. The method according to claim 16 , wherein the melanoma is BRAF-mutant melanoma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2025
From: ALUGUPALLI, AKHIL; ALUGUPALLI, KISHORE
To: SRIN THERAPEUTICS, INC.
Reel/Frame 072312/0785 →
Continuity (2)
Provisional Application 62802754 · Feb 8, 2019
Related Publication 20220193003A1 · Jun 23, 2022
References Cited (119)
US 8632825B2 · Velasco Diez et al. · 2014 [cited by applicant]
US 20150080265A1 · Elzinga et al. · 2015 [cited by applicant]
US 20160279073A1 · Donsky · 2016 [cited by examiner]
US 20160331720A1 · Hospodor · 2016 [cited by applicant]
US 20180296493A1 · Kaufman · 2018 [cited by applicant]
CA 3068383A1 · 2019 [cited by applicant]
GB 2386322 · 2003 [cited by applicant]
WO WO2001095899 · 2001 [cited by applicant]
WO WO2003063847 · 2003 [cited by applicant]
WO WO2003070232 · 2003 [cited by applicant]
WO WO2009147439 · 2009 [cited by applicant]
WO WO2015184127 · 2015 [cited by applicant]
WO WO2017068349 · 2017 [cited by applicant]
Rock, Front Pharmacol, 2016, 7:221 (Year: 2016). [cited by examiner]
Pisanti, Pharmacology and Therapeutics, 175, 2017, 133-150, of the record (Year: 2017). [cited by examiner]
Salminen, Cell. Mol. Life Sci. 65, 2008, 2979-2999 (Year: 2008). [cited by examiner]
De la Ossa, Journal of Controlled Release 161, 2012 (Year: 2012). [cited by examiner]
Choi, Biomolecules and Therapeutics, 16, 87-94, 2008 (Year: 2008). [cited by examiner]
He, Journal of Nutrition, vol. 127, Iss. 5, 1997 (Year: 1997). [cited by examiner]
Obembe, BJMMR, 7(1): 52-60, 2015 (Year: 2015). [cited by examiner]
Abel, A.M. et al., Natural Killer Cells: Development, Maturation, and Clinical Utilization, Front Immunol. Aug. 13, 2018;9:1869. [cited by applicant]
Abrams, D.I., Integrating cannabis into clinical cancer care. Curr Oncol, May 2016. 23(2): p. S8-S14. [cited by applicant]
Abrams, D.I., Using Medical Cannabis in an Oncology Practice. Oncology (Williston Park), Mar. 2016. 30(5): p. 397-404. [cited by applicant]
Agata, Y., et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. May 1996;8(5):765-72. [cited by applicant]
Allegrezza, M.J., et al., IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. Cancer Res, May 2016. 76(9): p. 2561-72. [cited by applicant]
Armstrong, J.L., et al., Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol, Jun. 2015. 135(6): p. 1629-1637. [cited by applicant]
Ascierto, P.A., et al., MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol, Mar. 2013. 14(3): p. 249-56. [cited by applicant]
Basu, S. and B.N. Dittel, Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res, Oct. 2011. 51(1): p. 26-38. [cited by applicant]
Basu, S., A. Ray, and B.N. Dittel, Cannabinoid Receptor 2 (CB2) Plays a Role in the Generation of Germinal Center and Memory B Cells, but Not in the Production of Antigen-Specific IgG and IgM, in Response to T-dependent… [cited by applicant]
Basu, S., A. Ray, and B.N. Dittel, Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses. J Immunol, Dec. 2011. 187(11): p. 572… [cited by applicant]
Bennett, F. et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J… [cited by applicant]
Brown, M. and Wittwer, C. Flow Cytometry: Principles and Clinical Applications in Hematology, Clin Chem. Aug. 2000;46(8 Pt 2):1221-9. [cited by applicant]
Campos, A.C., et al., Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res, Oct. 2016. 112: p. 119-127. [cited by applicant]
Carter, L. et al., PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol. Mar. 2002;32(3):634-43. [cited by applicant]
Catalanotti, F., et al., Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res, Apr. 2013. 19(8): p. 2257-64. [cited by applicant]
Chou, T. et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55. [cited by applicant]
ClinicalTrials.gov. A Study: Pure CBD as Single-agent for Solid Tumor, NCT02255292. Oct. 2, 2014. [cited by applicant]
Cooper, Z.A., et al., Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. Clin Cancer Res, Jul. 2015. 21(14): p. 3102-4. [cited by applicant]
Crawford, J., D.C. Dale, and G.H. Lyman, Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer, Jan. 2004. 100(2): p. 228-37. [cited by applicant]
Crosby, T., et al., Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev, 2000(2): p. CD001215. [cited by applicant]
Damsky, W.E. and M. Bosenberg, From bedding to bedside: genetically engineered mouse models of cancer inform concurrent clinical trials. Pigment Cell Melanoma Res, Jul. 2012. 25(4): p. 404-5. [cited by applicant]
Deiana, S., et al., Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitonea… [cited by applicant]
Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. Aug. 2002;8(8):793-800. [cited by applicant]
Dushyanthen, S., et al., Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nat Commun, Sep. 2017. 8(1): p. 606. [cited by applicant]
Ebert, P.J.R., et al., MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity, Mar. 2016. 44(3): p. 609-621. [cited by applicant]
Eisenstein, T.K. and Meissler, J.J. Effects of Cannabinoids on T-cell Function and Resistance to Infection. J Neuroimmune Pharmacol. Jun. 2015;10(2):204-16. [cited by applicant]
Elbaz, M., et al., TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. Oncotarget, May 2016. 9(71): p. 33459-33470. [cited by applicant]
Finak, G. et al. Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium. Scientific reports vol. 6 20686 (Feb. 2016). [cited by applicant]
Freeman, G.J. et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. J Exp Med, Oct. 2, 2000; 192 (7): 1027-1034. [cited by applicant]
Galluzzi, L., et al., Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell, Dec. 2015. 28(6): p. 690-714. [cited by applicant]
Hanus, L.O., Discovery and isolation of anandamide and other endocannabinoids. Chem Biodivers, Aug. 2007. 4(8): p. 1828-41. [cited by applicant]
Hartsough, E., Y. Shao, and A.E. Aplin, Resistance to RAF inhibitors revisited. J Invest Dermatol, Feb. 2014. 134(2): p. 319-325. [cited by applicant]
Haustein, M., et al., Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochem Pharmacol, Nov. 2014. 92(2): p. 312-25. [cited by applicant]
Hershman, D.L., et al., Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, Jun. 2014. … [cited by applicant]
Hu, G., G. Ren, and Y. Shi, The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene, Jan. 2011. 30(2): p. 139-41. [cited by applicant]
Hugo, W., et al., Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell, Sep. 2015. 162(6): p. 1271-85. [cited by applicant]
Hu-Lieskovan, S., et al., Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med, Mar. 2015. 7(279): p. 279ra41. [cited by applicant]
Huncharek, M., J.F. Caubet, and R. McGarry, Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Re… [cited by applicant]
Iffland, K. and F. Grotenhermen, An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res, Jun. 2017. 2(1): p. 139-154. [cited by applicant]
Kaplan, et al. Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J Pharmacol Exp Ther. Sep. 2003;306(3):1077-85. [cited by applicant]
Kaplan, et al. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol. Sep. 15, 2008;76(6):726-37. [cited by applicant]
Kirkwood, J.M., et al., Immunotherapy of cancer in 2012. CA Cancer J Clin, Sep.-Oct. 2012. 62(5): p. 309-35. [cited by applicant]
Kirkwood, J.M., et al., Next generation of immunotherapy for melanoma. J Clin Oncol, Jul. 2008. 26(20): p. 3445-55. [cited by applicant]
Knight, D.A., et al., Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest, Mar. 2013. 123(3): p. 1371-81. [cited by applicant]
Koya, R.C., et al., BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res, Aug. 2012. 72(16): p. 3928-37. [cited by applicant]
Laprairie, R.B., et al., Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol, Oct. 2015. 172(20): p. 4790-805. [cited by applicant]
Larkin, J., et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med, Jul. 2015. 373(1): p. 23-34. [cited by applicant]
Larkin, J., et al., Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med, Nov. 2014. 371(20): p. 1867-76. [cited by applicant]
Levine, N. and E.S. Greenwald, Mucocutaneous side effects of cancer chemotherapy. Cancer Treat Rev, Jun. 1978. 5(2): p. 67-84. [cited by applicant]
Loprinzi, C.L., et al., Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol, Oct. 2020. 38(28): p. 3325-3348. [cited by applicant]
Maida, V. and P.J. Daeninck, A user's guide to cannabinoid therapies in oncology. Curr Oncol, Dec. 2016. 23(6): p. 398-406. [cited by applicant]
Massi, P., A. Vaccani, and D. Parolaro, Cannabinoids, immune system and cytokine network. Curr Pharm Des, 2006. 12(24): p. 3135-46. [cited by applicant]
Massi, P., et al., Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther, Mar. 2004. 308(3): p. 838-45. [cited by applicant]
Massi, P., et al., The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci, Sep. 2006. 63(17): p. 2057-66. [cited by applicant]
Mauch, P., et al., Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys, Mar. 1995. 31(5): p. 1319-39. [cited by applicant]
McAllister, S.D., et al., Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther, Nov. 2007. 6(11): p. 2921-7. [cited by applicant]
McAllister, S.D., et al., The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. J Neuroimmune Pharmacol . Jun. 2015;10(2):255-67. [cited by applicant]
Mechoulam, R., L.A. Parker, and R. Gallily, Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol, Nov. 2002. 42(S1): p. 11S-19S. [cited by applicant]
Mentzelopoulos, A., et al., Chemotherapy-Induced Brain Effects in Small-Cell Lung Cancer Patients: A Multimodal MRI Study. Brain Topogr, Mar. 2021. 34(2): p. 167-181. [cited by applicant]
Michaelis, M., et al., Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function. J Pharm Pharm Sci, Apr. 2014. 17(1): p. 154-68. [cited by applicant]
Millar, S.A., et al., A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol, Nov. 2018. 9: p. 1365. [cited by applicant]
Molyneux, G., et al., Haemotoxicity of busulphan, doxorubicin, cisplatin and cyclophosphamide in the female BALB/c mouse using a brief regimen of drug administration. Cell Biol Toxicol, Feb. 2011. 27(1): p. 13-40. [cited by applicant]
Muppidi, J.R., et al., Cannabinoid receptor 2 positions and retains marginal zone B cells within the splenic marginal zone. J Exp Med, Sep. 2011. 208(10): p. 1941-8. [cited by applicant]
Neurobiologix ‘Pharmaceutical grade: What it is and how it benefits me’ Jul. 21, 2018 (Jul. 21, 2018) retreived from <web.archive.org> on Apr. 8, 2020 (Apr. 8, 2020). [cited by applicant]
Nikiforov, Y.E., Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol, May 2008. 21 Suppl 2: p. S37-43. [cited by applicant]
Okazaki, T, Iwai Y, Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol. Dec. 2002; 14(6):779-82. [cited by applicant]
Pisanti, S., et al., Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther, Jul. 2017. 175: p. 133-150. [cited by applicant]
Pond, S.M. and T.N. Tozer, First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet, Jan.-Feb. 1984. 9(1): p. 1-25. [cited by applicant]
Ramer, R., et al., Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol, Apr. 2010. 79(7): p. 955-66. [cited by applicant]
Ramer, R., et al., Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J, Apr. 2012. 26(4): p. 1535-48. [cited by applicant]
Ramer, R., et al., COX-2 and PPAR-gamma confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther, Jan. 2013. 12(1): p. 69-82. [cited by applicant]
Ramer, R., et al., Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm Res, Oct. 2010. 27(10): p. 2162-74. [cited by applicant]
Rock, E.M. and L.A. Parker, Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting. Front Pharmacol, Jul. 2016. 7: p. 221. [cited by applicant]
Rowland, M., Influence of route of administration on drug availability. J Pharm Sci, Jan. 1972. 61(1): p. 70-4. [cited by applicant]
Russo, E.B., Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol, Aug. 2011. 163(7): p. 1344-64. [cited by applicant]
Schatz, A.R., et al., Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol, Feb. 1997. 142(2): p. 278-87. [cited by applicant]
Sekhon, B. Surfactants: Pharmaceutical and Medicinal Aspects. Journal of Pharmaceutical Technology/ Research and Management, May 2013, vol. 1, pp. 43-68. [cited by applicant]
Shrivastava, A., et al., Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther, Jul. 2011. 10(7): p. 1161-72. [cited by applicant]
Simkins, T.J., et al., Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CB1 and CB2 Cannabinoid Receptors. J Neuroimmune Pharmacol, Dec. 2016. 11(4): p. 669-679. [cited by applicant]
Simmerman, E., et al., Cannabinoids as a Potential New and Novel Treatment for Melanoma: A Pilot Study in a Murine Model. J Surg Res, Mar. 2019. 235: p. 210-215. [cited by applicant]
Śledziński, P., et al. The current state and future perspectives of cannabinoids in cancer biology. Cancer Med. Mar. 2018;7(3):765-775. Epub Feb. 23, 2018. [cited by applicant]
Solinas, M., et al., Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol, Nov. 2012. 167(6): p. 1218-31. [cited by applicant]
Su, Y., et al., RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res, Aug. 2012. 18(8): p. 2184-98. [cited by applicant]
Sule-Suso, J., et al., Striking lung cancer response to self-administration of cannabidiol: A case report and literature review. SAGE Open Med Case Rep, Feb. 2019. 7: p. 2050313X19832160. [cited by applicant]
Thomas, A., et al., Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol, Mar. 2007. 150(5): p. 613-23. [cited by applicant]
Vaccani, A., et al., Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol, Apr. 2005. 144(8): p. 1032-6. [cited by applicant]
Velasco, G., et al. Anticancer mechanisms of cannabinoids, Curr Oncol. Mar. 2016;23(2):S23-32. [cited by applicant]
Wang, D., et al., Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta, Aug. 2007. 1773(8): p. 1248-55. [cited by applicant]
Wang, M., et al., Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol, May 1995. 154(9): p. 4685-92. [cited by applicant]
Wang, M., et al., Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. J Immunother Emphasis Tumor Immunol, Oct. 1995. 18(3): p. 139-46. [cited by applicant]
Ward, S.J., et al., Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol, Feb. 2014. 171(3): p. 636-45. [cited by applicant]
Weston, W.L., et al. Quantitative assays of human monocyte-macrophage function. J Immunol Methods. Sep. 1975;8(3):213-22. [cited by applicant]
Wikipedia ‘Polysorbate 80’ Dec. 3, 2018 (Dec. 3, 2018). [cited by applicant]
Wolchok, J.D., et al., Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med, Oct. 2017. 377(14): p. 1345-1356. [cited by applicant]
Yang, Y.T. and J.P. Szaflarski, The US Food and Drug Administration's Authorization of the First Cannabis-Derived Pharmaceutical: Are We Out of the Haze? JAMA Neurol, Feb. 2019. 76(2): p. 135-136. [cited by applicant]
Yu, Y. et al. A Protocol for the Comprehensive Flow Cytometric Analysis of Immune Cells in Normal and Inflamed Murine Non-Lymphoid Tissues. PLoS One. Mar. 3, 2016;11(3):e0150606. [cited by applicant]
Zhou, X. et al. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care. Sep. 2010;13(5):541-7. [cited by applicant]
Zhu, W., et al., A mouse model for juvenile doxorubicin-induced cardiac dysfunction. Pediatr Res, Nov. 2008. 64(5): p. 488-94. [cited by applicant]
International Search Report and Written Opinion dated August Jul. 6, 2020 issued in International Patent Application No. PCT/US20/17311. [cited by applicant]